Multiple Myeloma Survival With Stem Cell Transplant

The transplant of this kind is the standard treatment for patients with various myeloma.

Multiple myeloma survival with stem cell transplant. The standard of care for fit multiple myeloma patients is to receive high dose chemotherapy hdt with autologous stem cell rescue otherwise known as autologous stem cell transplant asct after completion of induction therapy. When stem cell transplants were first developed the new stem cells came from bone marrow and so this was known as a bone marrow. All things considered while the autologous transplant can make the myeloma go away for a period of time even years it does not cure the growth and inevitably the myeloma back. The long term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997 through with the introduction of new medicines a large review study reports.

Autologous stem cell transplantation is more common for multiple myeloma but either type of transplant can be used. A stem cell transplant replaces unhealthy blood cells with healthy ones. In a stem cell transplant the patient gets high dose chemotherapy to kill the cells in the bone marrow. Multiple myeloma survival rate after stem cell transplant.

Stem cell transplant for multiple myeloma. We here analyze factors influencing survival in 865 newly diagnosed mm patien. It isn t a cure but compared to chemotherapy alone a. A population based study published correction appears in blood.

The widespread use of high dose therapy and autologous stem cell transplantation asct as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma mm enabling long term survival. People who have autologous or allogeneic transplants first receive high dose chemotherapy to kill the cancer cells. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma. Older patients and those with low risk disease show the greatest gains over time while people with high risk factors showed the least change its researchers said.

Then the patient receives new healthy blood forming stem cells.